TNFSF11 and Bartsocas-Papas syndrome 1: Among the MRONJ-positive drugs, frequently reported drugs included BPs, such as zoledronic acid, alendronic acid, and ibandronic acid; the anti-receptor activator of nuclear factor kappa B ligand (RANKL) antibody denosumab; anticancer drugs like sunitinib, bevacizumab, everolimus, and letrozole; as well as corticosteroids, such as dexamethasone and prednisolone (Table 1).